Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases

AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates

Top-line Phase 2a Data from Etokimab (ANB020) in Eosinophilic Asthma Expected in Third Quarter of 2018 Etokimab Clinical Development Program Expanded to Include Chronic Rhinosinusitis with Nasal Polyps Commercial Considerations Led to Deprioritization of Further AnaptysBio-Sponsored Clinical

AnaptysBio to Present at the 2018 Wedbush PacGrow Healthcare Conference

SAN DIEGO , Aug. 06, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference

SAN DIEGO , May 30, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will